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Table
Fatty acid transport, oxidation, andmitochondrial biogenesis in GVHD Tcells
Parameter Naïve* GVHD P value
Fatty Acid Transport
Slc27a2 mRNA 1.0  0.8 42.0  6.7 1.0 >1.0
Transport (% cells
BoDipyHi)y
0.7  0.05 44.3  6.9 0.003
Fatty Acid Oxidation
CPT2 enzyme ratio 1.0  1.7 103  31 0.005
Oxidation (cpm x10-5)z 1.1  0.2 1.9  0.3 0.02
Mitochondrial Biogenesis
Mitochondrial Massx 47.6  14.2 66.3  5.9 0.04
Mitochondrial/nuclear
DNA
1.0  0.07 2.7  0.52 < 0.0001
PGC-1a ratio 1.0  1.3 3900  1200 0.005
* Naïve cells served as controls (values set to 1.0) for mRNA levels and all
ratios
y Uptake of BoDipyC1-C12, a fatty acid analog, was measured by ﬂow
cytometry
z Oxidation measured by the conversion of 3H-palmitate to 3H20,
expressed as cpm of 3H2O
x Mitochondrial mass measured as the % of cells Mitotracker GreenHi
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compared to resting (naïve) T cells (see Table). Donor T cells
also increased levels of enzymes necessary for FA oxidation
(e.g. CPT2) 100-fold and oxidized more FAs. Mitochondrial
mass (required for FA oxidation) increased in donor T cells, as
did the ratio of mitochondrial to nuclear DNA, and the
expression of PGC-1a, a key regulator of mitochondrial
biogenesis. Importantly, T cells proliferating during routine
immune reconstitution (following syngeneic BMT) mini-
mally increased FA transport (10% vs. 40% in GVHD T cells).
Finally, inhibition of FA oxidation in vivo, through irreversible
blockade of CPT1 with etomoxir, decreased the total number
of well-divided donor Tcells after a single dose. Furthermore,
two weeks of etomoxir treatment, beginning on day +7,
improved both GVHD clinical score (1.1 vs. 3.8 in untreated
animals, P ¼ .02) and weight loss at day 40. In total, these
data demonstrate that GVHD T cells up-regulate FA metab-
olism in vivo and that proliferating, donor cells can be
selectively eliminated through inhibition of FA oxidation. Our
data provide novel insights into the metabolism of lympho-
cytes activated in vivo and show that inhibition of FA
oxidationmay be a therapeutic target for the prevention and/
or treatment of GVHD.
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Acute graft-versus-host disease (aGvHD) of the gut based
only on clinical symptoms may be difﬁcult to distinguish
from other causes. Assessing response to treatment may be
hampered by persistent diarrhea resulting from damage to
the gut in the absence of ongoing aGvHD. Histological
examination of gut biopsies conﬁrm the diagnosis but are
invasive. We aimed to determine the importance of biopsies
to evaluate the response to treatment with mesenchymal
stromal cells (MSC) and assess the usefulness of biomarkers.In this study, 18 patients received MSC for severe steroid
refractory aGvHD of the gut (conﬁrmed by a biopsy in 16
patients). In 89% (n¼16) diarrhea persisted after the ﬁrst MSC
and a second (and in 3 cases a third) MSC infusion was
considered. A second gut biopsy was taken from 9 patients
before subsequent MSC infusion and in 6 of these biopsies
(67%) no signs of aGvHD were seen. The 3 patients with
biopsy conﬁrmed active aGvHD showed a response after
a subsequent MSC infusion. Nine out of 18 patients showed
a complete (CR), 4 a partial response (PR) and 5 no response
(NR) at 28 days after starting MSC therapy (1-3 infusions).
Our data suggests that without biopsy evaluation after MSC
infusion, the response to treatment may be underestimated
and over treatment occurs. In contrast patients with a posi-
tive biopsy may beneﬁt from additional MSC treatment.
However, a biopsy of children with aGvHD is not always
feasible. Therefore, the value of previously reported
biomarkers was assessed in our patient cohort (sIL2Ra,
sCK18F, sTNFR1). Patient samples were longitudinally
measured starting before SCT until 50 days after the last MSC
infusion. At the start of aGvHD, serum concentrations of sIL-
2Ra, sTNFR1 and soluble cytokeratin 18 fragment (sCK18F)
were signiﬁcantly elevated compared with samples before
onset. The response at day 28 can be predicted using sIL-2Ra
concentrations on day 7. Patients with CR/PR (n¼13) have
lower sIL-2Ra concentrations compared to non-responders
(n¼5) (P ¼ .015). The value of REG-3a in predicting the
occurrence of gut aGvHD and monitoring the effect of
treatment is currently being investigated.
In our opinion biomarkers can contribute to the diagnostic
process, but biopsy remains the golden standard for the
diagnosis and short term response to treatment of aGvHD.
Sequential biopsies should be included in randomized
controlled trials to validate the importance of biomarkers in
monitoring response to experimental cellular therapy.423
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